reserpine has been researched along with Dyskinesia, Drug-Induced in 87 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 74-year-old woman developed a slowly progressive hemichorea starting 3 weeks after discontinuation of low-dose amitriptyline and perphenazine." | 7.67 | A case of progressive hemichorea responsive to high-dose reserpine. ( Friedman, JH, 1986) |
| "Reserpine was added for both antipsychotic coverage and reported beneficial effects in the treatment of TD." | 5.27 | Alprazolam reversal of reserpine-induced depression in patients with compensated tardive dyskinesia. ( Holt, RJ, 1984) |
| "The nigrostriatal dopaminergic system seems to be involved in both reserpine-induced orofacial dyskinesia in normal rats and in the pathogenesis of hypertension in spontaneously hypertensive rats." | 3.70 | Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats. ( Frussa-Filho, R; Piovezan, RD; Queiroz, CM, 1998) |
| "A 74-year-old woman developed a slowly progressive hemichorea starting 3 weeks after discontinuation of low-dose amitriptyline and perphenazine." | 3.67 | A case of progressive hemichorea responsive to high-dose reserpine. ( Friedman, JH, 1986) |
| "Agmatine is an endogenous arginine metabolite that emerges as neuromodulator and a promising agent to manage diverse central nervous system disorders by modulating nitric oxide (NO) pathway, glutamate NMDA receptors and oxidative stress." | 1.43 | Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors. ( Blum-Silva, CH; Colle, D; Cunha, AS; Cunha, MP; Farina, M; Matheus, FC; Moretti, M; Poli, A; Prediger, RD; Reginatto, FH; Rodrigues, AL; Sampaio, TB; Sandjo, LP; Santos, DB, 2016) |
| "Gallic acid is a natural polyphenolic acid found in gall nuts, sumac, oak bark, tea leaves, grapes and wine, with potent antioxidant and antiapoptotic activity." | 1.39 | Gallic acid decreases vacuous chewing movements induced by reserpine in rats. ( Bürger, ME; de Freitas, CM; Fachinetto, R; Ferrari, MC; Peroza, LR; Reckziegel, P; Schaffer, LF, 2013) |
| "Reserpine-treated animals also showed poor retention of memory in the elevated plus maze paradigm." | 1.37 | Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats. ( Barhate, SA; Kasture, SB; Mahajan, MS; Mohan, M; Sanghavi, CR, 2011) |
| "Reserpine treatment is a putative animal model of orofacial dyskinesia, tremor, and Parkinsonism." | 1.37 | Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. ( Barbosa, NB; Barreto, KP; Burger, ME; Busanello, A; Fachinetto, R; Farias, LE; Peroza, LR, 2011) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects." | 1.35 | Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats. ( Dwivedi, S; Kawale, LA; Nade, VS; Upasani, CD; Yadav, AV, 2009) |
| "Reserpine treated animals also showed poor retention of memory in the elevated plus maze task paradigm." | 1.33 | Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. ( Kulkarni, SK; Naidu, PS; Singh, A, 2006) |
| "Treatment with baclofen (4 mg/kg) did not modify spontaneous VCM." | 1.33 | Effects of baclofen on reserpine-induced vacuous chewing movements in mice. ( Abílio, VC; Castro, JP; Frussa-Filho, R; Fukushiro, DF; Medrano, WA; Ribeiro, Rde A; Silva, RH, 2006) |
| "Reserpine-treated animals also showed poor retention of memory in elevated plus-maze task paradigm." | 1.32 | Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin. ( Kulkarni, SK; Naidu, PS; Singh, A, 2004) |
| "The effects of a previous long-term administration of the mitochondrial toxin 3-nitropropionic acid were studied on an animal model of tardive dyskinesia, i." | 1.31 | The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats. ( Abilio, VC; Araujo, CC; Bergamo, M; Calvente, PR; D'Almeida, V; Frussa, FR; Ribeiro, Rde A, 2002) |
| "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0." | 1.31 | Behavioral effects of MK-801 on reserpine-treated mice. ( Andreatini, R; Andreazza, AP; Dutra, RC; Tufik, S; Vital, MA, 2002) |
| "Rats treated with reserpine develop spontaneous orofacial dyskinesia that has features similar to tardive dyskinesia (TD) in humans." | 1.29 | Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. ( Castañeda, E; Davis, DA; Neisewander, JL, 1994) |
| "Treatment with reserpine successfully controlled the dyskinetic movements." | 1.28 | Clenbuterol-induced tardive dyskinesia. ( Gatto, E; Gene, R; Micheli, F; Pardal, MF, 1991) |
| "The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats." | 1.28 | Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. ( Lucki, I; McGonigle, P; Neisewander, JL, 1991) |
| "Reserpine was added for both antipsychotic coverage and reported beneficial effects in the treatment of TD." | 1.27 | Alprazolam reversal of reserpine-induced depression in patients with compensated tardive dyskinesia. ( Holt, RJ, 1984) |
| "Treatment with reserpine and discontinuance of antipsychotic drugs was useful for patients with severe symptoms of tardive dyskinesia or akathisia; complete remission with elimination of all drugs was achieved in 4 of 19 treated patients, without recurrence of symptoms." | 1.27 | A therapeutic approach to tardive dyskinesia. ( Fahn, S, 1985) |
| "Tetrabenazine and reserpine were most effective (greater than 50% response rate) in controlling dystonia." | 1.27 | Natural history and treatment of tardive dystonia. ( Burke, RE; Fahn, S; Kang, UJ, 1986) |
| "Tetrabenazine and reserpine were most effective (greater than 50% response rate) in controlling dystonia." | 1.27 | Tardive dystonia. ( Burke, RE; Fahn, S; Kang, UJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (36.78) | 18.7374 |
| 1990's | 13 (14.94) | 18.2507 |
| 2000's | 28 (32.18) | 29.6817 |
| 2010's | 14 (16.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sayeh, HG | 1 |
| Rathbone, J | 1 |
| Soares-Weiser, K | 1 |
| Bergman, H | 1 |
| Santos, JR | 1 |
| Cunha, JA | 1 |
| Dierschnabel, AL | 1 |
| Campêlo, CL | 1 |
| Leão, AH | 1 |
| Silva, AF | 1 |
| Engelberth, RC | 1 |
| Izídio, GS | 1 |
| Cavalcante, JS | 1 |
| Abílio, VC | 12 |
| Ribeiro, AM | 1 |
| Silva, RH | 9 |
| Konieczny, J | 1 |
| Lenda, T | 1 |
| Cunha, AS | 1 |
| Matheus, FC | 1 |
| Moretti, M | 1 |
| Sampaio, TB | 1 |
| Poli, A | 1 |
| Santos, DB | 1 |
| Colle, D | 1 |
| Cunha, MP | 1 |
| Blum-Silva, CH | 1 |
| Sandjo, LP | 1 |
| Reginatto, FH | 1 |
| Rodrigues, AL | 1 |
| Farina, M | 1 |
| Prediger, RD | 1 |
| Nade, VS | 1 |
| Dwivedi, S | 1 |
| Kawale, LA | 1 |
| Upasani, CD | 1 |
| Yadav, AV | 1 |
| Syu, A | 1 |
| Ishiguro, H | 1 |
| Inada, T | 1 |
| Horiuchi, Y | 1 |
| Tanaka, S | 1 |
| Ishikawa, M | 1 |
| Arai, M | 1 |
| Itokawa, M | 1 |
| Niizato, K | 1 |
| Iritani, S | 1 |
| Ozaki, N | 1 |
| Takahashi, M | 1 |
| Kakita, A | 1 |
| Takahashi, H | 1 |
| Nawa, H | 1 |
| Keino-Masu, K | 1 |
| Arikawa-Hirasawa, E | 1 |
| Arinami, T | 1 |
| Ferger, B | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Alachkar, A | 1 |
| Brotchie, JM | 2 |
| Jones, OT | 1 |
| Sanghavi, CR | 1 |
| Barhate, SA | 1 |
| Mahajan, MS | 1 |
| Mohan, M | 1 |
| Kasture, SB | 2 |
| Busanello, A | 1 |
| Barbosa, NB | 1 |
| Peroza, LR | 2 |
| Farias, LE | 1 |
| Burger, ME | 5 |
| Barreto, KP | 1 |
| Fachinetto, R | 5 |
| Pereira, RP | 2 |
| de Souza Prestes, A | 1 |
| Wagner, C | 1 |
| Sudati, JH | 1 |
| Boligon, AA | 1 |
| Athayde, ML | 1 |
| Morsch, VM | 1 |
| Rocha, JB | 5 |
| Broadstock, M | 1 |
| Austin, PJ | 1 |
| Betts, MJ | 1 |
| Duty, S | 3 |
| Patil, RA | 1 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Reckziegel, P | 1 |
| Schaffer, LF | 1 |
| Ferrari, MC | 1 |
| de Freitas, CM | 1 |
| Murray, TK | 1 |
| Messenger, MJ | 1 |
| Ward, MA | 1 |
| Woodhouse, S | 1 |
| Osborne, DJ | 1 |
| O'Neill, MJ | 1 |
| Araujo, CC | 2 |
| Bergamo, M | 3 |
| Calvente, PR | 2 |
| D'Almeida, V | 4 |
| Ribeiro, Rde A | 6 |
| Frussa-Filho, R | 13 |
| Alves, A | 2 |
| Callegari, L | 2 |
| Athayde, FR | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 1 |
| Carvalho, RC | 4 |
| Barbosa, PN | 1 |
| Peixoto, MF | 2 |
| Naidu, PS | 4 |
| Singh, A | 2 |
| Kulkarni, SK | 4 |
| Grassl, C | 3 |
| Calzavara, MB | 1 |
| Registro, S | 2 |
| Araujo, NP | 2 |
| Pereira, RC | 1 |
| Gonzalez, C | 1 |
| Bellot, RG | 1 |
| Castro, JP | 3 |
| Fukushiro, DF | 4 |
| Rodrigues, MS | 2 |
| Chinen, CC | 3 |
| Burger, M | 1 |
| Calegari, L | 1 |
| Paixão, MW | 1 |
| Braga, AL | 1 |
| Fachineto, R | 1 |
| Johnston, TH | 1 |
| Lee, J | 1 |
| Gomez-Ramirez, J | 1 |
| Fox, SH | 1 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Faria, RR | 2 |
| Zanier-Gomes, PH | 1 |
| Medrano, WA | 2 |
| Negrão, LT | 1 |
| de Castro, JP | 1 |
| Gomes, PH | 1 |
| de Carvalho, Rde C | 1 |
| Natesan, S | 1 |
| Svensson, KA | 1 |
| Reckless, GE | 1 |
| Nobrega, JN | 1 |
| Barlow, KB | 1 |
| Johansson, AM | 1 |
| Kapur, S | 1 |
| Preskorn, SH | 1 |
| Teixeira, AM | 1 |
| Trevizol, F | 1 |
| Colpo, G | 1 |
| Garcia, SC | 1 |
| Charão, M | 1 |
| Nasrallah, HA | 1 |
| Pappas, NJ | 1 |
| Crowe, RR | 1 |
| Donatelli, A | 1 |
| Geisen, L | 1 |
| Feuer, E | 1 |
| Johnson, JM | 1 |
| Bacher, NM | 2 |
| Lewis, HA | 1 |
| Holt, RJ | 1 |
| Goetz, CG | 1 |
| Klawans, HL | 2 |
| Andrade, LA | 1 |
| Bertolucci, PH | 1 |
| Pereira, JS | 1 |
| Reches, A | 1 |
| Hassan, MN | 1 |
| Jackson, V | 1 |
| Fahn, S | 7 |
| Dilsaver, SC | 1 |
| Greden, JF | 1 |
| Huang, CC | 2 |
| Wang, RI | 2 |
| Hasegawa, A | 2 |
| Alverno, L | 2 |
| Peters, HA | 1 |
| LaHoste, GJ | 1 |
| Marshall, JF | 1 |
| Neisewander, JL | 4 |
| Castañeda, E | 2 |
| Davis, DA | 2 |
| Kaur, S | 1 |
| Starr, MS | 1 |
| Starr, BS | 1 |
| Elson, HJ | 1 |
| Sussman, AN | 2 |
| Healy, DJ | 1 |
| Dalack, GW | 1 |
| Meador-Woodruff, JH | 1 |
| Vital, MA | 2 |
| Palermo-Neto, J | 1 |
| Tran-Nguyen, LT | 1 |
| Queiroz, CM | 2 |
| Piovezan, RD | 1 |
| Rojas, VM | 1 |
| Davies, RK | 1 |
| Dawson, L | 1 |
| Chadha, A | 1 |
| Megalou, M | 1 |
| Simpson, GM | 1 |
| Raghavendra, V | 1 |
| Frussa, FR | 1 |
| Torres-Leite, D | 2 |
| Claro, FT | 1 |
| Carvalho, Rde C | 1 |
| Dutra, RC | 1 |
| Andreazza, AP | 1 |
| Andreatini, R | 1 |
| Tufik, S | 2 |
| Vera, JA | 1 |
| Ferreira, LS | 1 |
| Duarte, CR | 1 |
| Martins, CR | 1 |
| Bignotto, M | 1 |
| Kobayashi, RM | 1 |
| Carroll, BJ | 1 |
| Curtis, GC | 1 |
| Kokmen, E | 1 |
| Casey, DE | 2 |
| Jus, A | 1 |
| Jus, K | 1 |
| Fontaine, P | 1 |
| Rosin, AJ | 1 |
| Bourgeois, M | 1 |
| Böszörményi, Z | 1 |
| Kannari, K | 1 |
| Markstein, R | 1 |
| Micheli, F | 1 |
| Gatto, E | 1 |
| Gene, R | 1 |
| Pardal, MF | 1 |
| Lucki, I | 1 |
| McGonigle, P | 1 |
| Field, PB | 1 |
| Elkashef, A | 1 |
| Reddi, K | 1 |
| Jankovic, J | 1 |
| Casabona, J | 1 |
| Kang, UJ | 2 |
| Burke, RE | 2 |
| de Yebenes, JG | 1 |
| Jackson-Lewis, V | 1 |
| Jorge, P | 1 |
| Mena, MA | 1 |
| Reiriz, J | 1 |
| Rushkevich, IuE | 1 |
| Friedman, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
5 reviews available for reserpine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Anti-Dyskinesia Agents; Antipsychotic Agents; Celiprolol; Disease Prog | 2018 |
Psychiatric uses of antiadrenergic and adrenergic blocking drugs.
Topics: Adult; Alcohol Amnestic Disorder; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 1984 |
[Tardive dyskinesia: I. Physiopathology and treatment].
Topics: Animals; Antipsychotic Agents; Baclofen; Binding Sites; Dopamine; Dyskinesia, Drug-Induced; Humans; | 1984 |
The treatment of tardive dyskinesia and tardive dystonia.
Topics: Adult; Akathisia, Drug-Induced; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Decisi | 2000 |
Tardive dyskinesia: epidemiologic factors as a guide for prevention and management.
Topics: Age Factors; Animals; Antipsychotic Agents; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug | 1985 |
2 trials available for reserpine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Psychiatric uses of antiadrenergic and adrenergic blocking drugs.
Topics: Adult; Alcohol Amnestic Disorder; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 1984 |
Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.
Topics: Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Dyskin | 1981 |
81 other studies available for reserpine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Cognition; Data Interpretation, Statistical; Dyskinesia | 2013 |
Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Brain; Catalepsy; Disease Mod | 2013 |
Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors.
Topics: Agmatine; Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Do | 2016 |
Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Hi | 2009 |
Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Cholinesterase Inhibitors; Dyskinesia, Drug-Induced; Female; Genetic | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxyla | 2010 |
Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Catalase; Cognition Disorders; Dose-Response Relatio | 2011 |
Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Mastication; Mice; Motor | 2011 |
Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Male; Masti | 2011 |
Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitator | 2012 |
Protective effect of Rubia cordifolia on reserpine-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Dyskinesia, Drug-Induced; Lipid Peroxidation; Locomotion; Plant Extracts; Rat | 2012 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Gallic acid decreases vacuous chewing movements induced by reserpine in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antioxidants; Antipsychotic Agents; Brain; Disease Models, An | 2013 |
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.
Topics: Amino Acids; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds, Heterocycli | 2002 |
Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dyskin | 2003 |
Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
Topics: Adrenergic Uptake Inhibitors; Animals; Antioxidants; Azoles; Corpus Striatum; Disease Models, Animal | 2003 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relations | 2003 |
Effects of valproic acid on an animal model of tardive dyskinesia.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 2003 |
Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Blood Proteins; Catalase; Cognition Disorders; Dysk | 2004 |
Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia.
Topics: Aging; Amitrole; Animals; Catalase; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; | 2004 |
Effects of topiramate on oral dyskinesia induced by reserpine.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relat | 2004 |
Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide.
Topics: Age Factors; Aging; Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Benzene Derivativ | 2004 |
Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Dyskines | 2005 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Age | 2005 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
Effects of gabaergic drugs on reserpine-induced oral dyskinesia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Baclofen; Behavior, Animal; Diazepam; Dose-Resp | 2005 |
Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity.
Topics: Animals; Ascorbic Acid; Catalase; Corpus Striatum; Dyskinesia, Drug-Induced; Male; Rats; Rats, Wista | 2005 |
Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction.
Topics: Animals; Antioxidants; Brain; Cognition Disorders; Dyskinesia, Drug-Induced; Glutathione; Male; Malo | 2006 |
Effects of baclofen on reserpine-induced vacuous chewing movements in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Baclofen; Brain; Brain Chemistry; Dose-Response Relationship, | 2006 |
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor sid
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Binding, Competitive; Dihydroxyphenylalanine; Dop | 2006 |
The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol.
Topics: Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Europe; Haloperidol; History, 20th C | 2007 |
Influence of chronic exercise on reserpine-induced oxidative stress in rats: behavioral and antioxidant evaluations.
Topics: Animals; Antioxidants; Antipsychotic Agents; Brain Chemistry; Catalase; Dyskinesia, Drug-Induced; Gl | 2008 |
Oculogyric dystonia in tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Male; Opht | 1980 |
Case report of adverse effect of reserpine on tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Receptors, Dopamine; Reserpine | 1983 |
Reserpine and tardive dyskinesia.
Topics: Acute Disease; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Reserpine; Substance Withdraw | 1984 |
Alprazolam reversal of reserpine-induced depression in patients with compensated tardive dyskinesia.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Depression; Dyskinesia, Drug-Induced; Human | 1984 |
Tardive dyskinesia.
Topics: Antipsychotic Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Reserpine; Schizoph | 1984 |
Lithium interferes with reserpine-induced dopamine depletion.
Topics: Adult; Animals; Bipolar Disorder; Corpus Striatum; Dopamine; Dopamine Antagonists; Dyskinesia, Drug- | 1983 |
Possible cholinergic mechanism in reserpine and tardive dyskinesia.
Topics: Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Receptors, Dopamine; Receptors, Muscarinic; Reser | 1984 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combinat | 1983 |
Questioning reserpine's adverse effect on tardive dyskinesia.
Topics: Acute Disease; Dyskinesia, Drug-Induced; Humans; Reserpine | 1983 |
Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.
Topics: Adult; Aged; Double-Blind Method; Drug Evaluation; Dyskinesia, Drug-Induced; Humans; Methyldopa; Mid | 1980 |
Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Dopamine Agoni | 1994 |
Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; Disease Models, Animal; Dose-Respon | 1994 |
Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dizocilpine Maleat | 1994 |
Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia.
Topics: Adrenergic Agents; Amphetamine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Dru | 1996 |
Clozapine-reserpine combination for refractory psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; | 1997 |
Effects of monosialoganglioside on a new model of tardive dyskinesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Disease Models, Animal; Dysk | 1997 |
Acute reserpine administration elicits long-term spontaneous oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Male; Rats; Rats, Sprague- | 1997 |
Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Facial Muscles; Hyper | 1998 |
Reserpine treatment of comorbid Tourette's disorder and tardive dystonia.
Topics: Adrenergic Uptake Inhibitors; Adult; Comorbidity; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; H | 1999 |
Effects of buspirone on an animal model of tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Buspirone; Disease Models, Animal; Dopamine; Dyskinesia, Drug | 1999 |
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Cyclopropanes; Dyskinesia, Drug-Induced; Glycine; In | 2000 |
Animal models of tardive dyskinesia--a review.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free Radicals; gamm | 2001 |
Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Antineoplastic Agents; Dose-Res | 2001 |
The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Convulsants; Disease Models, Animal; Drug Synergism; Dyskines | 2002 |
Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Cognition; Dyskinesia, Drug-Induced; Female; Male | 2002 |
Behavioral effects of MK-801 on reserpine-treated mice.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, | 2002 |
Effects of melatonin on orofacial movements in rats.
Topics: Age Factors; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Lighting; Lipid Peroxidation; Male; | 2002 |
Drug therapy of tardive dyskinesia.
Topics: Age Factors; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Haloperidol; Humans; L | 1977 |
Paradoxical response to dopamine agonists in tardive dyskinesia.
Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Apomorphine; Benztropine; Clozapine; Deanol; Dextroamp | 1977 |
Managing tardive dyskinesia.
Topics: Antipsychotic Agents; Choline; Deanol; Dyskinesia, Drug-Induced; Humans; Lithium; Receptors, Dopamin | 1978 |
Long term treatment of tardive dyskinesia.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesi | 1979 |
Treatment of dyskinetic and choreatic movement disorders in adults.
Topics: Adult; Aged; Athetosis; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskine | 1978 |
[Tardive Dyskinesia induced by neuroleptics: a survey of 3140 patients in a psychiatric hospital].
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Diagnosis, Differential; Dyskine | 1977 |
Treatment of tardive dyskinesia with combined reserpine and alpha-methyltyrosine.
Topics: Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Methyltyrosines; Reserpine | 1978 |
[Pharmacogenic tardive dyskinesias and their management].
Topics: Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female | 1975 |
Therapeutic approaches to neuroleptic-induced tardive dyskinesias.
Topics: Butyrophenones; Dyskinesia, Drug-Induced; Humans; Parasympatholytics; Reserpine; Time Factors; Tranq | 1976 |
Dopamine agonists potentiate antiakinetic effects of competitive NMDA-antagonists in monoamine-depleted mice.
Topics: 2-Amino-5-phosphonovalerate; alpha-Methyltyrosine; Animals; Binding, Competitive; Caudate Nucleus; D | 1991 |
Clenbuterol-induced tardive dyskinesia.
Topics: Aged; Clenbuterol; Dyskinesia, Drug-Induced; Humans; Male; Reserpine | 1991 |
Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain; Caudat | 1991 |
Possible enhancing effects of diazepam with reserpine in a chronic schizophrenic patient with tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Diazepam; Drug Therapy, Combination; Dyskinesia, Drug- | 1989 |
A therapeutic approach to tardive dyskinesia.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Colitis; Depressive Disorder; Dyskinesia | 1985 |
Late onset involuntary movements in chronic schizophrenia: age-related vulnerability to "tardive" dyskinesia independent of extent of neuroleptic medication.
Topics: Age Factors; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Middle Aged; Reserpine; Schizop | 1985 |
Coexistent tardive dyskinesia and parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levo | 1987 |
Natural history and treatment of tardive dystonia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Dysto | 1986 |
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Brain Diseases; Catheterization; Cerebral Ventricles; Disease Models, | 1988 |
Tardive dystonia.
Topics: Adolescent; Adult; Age Factors; Aged; Dopamine Antagonists; Dyskinesia, Drug-Induced; Dystonia; Dyst | 1988 |
[Age characteristics of the development of a reserpine model of parkinsonism in rats].
Topics: Aging; Animals; Caudate Nucleus; Dyskinesia, Drug-Induced; Globus Pallidus; Male; Parkinson Disease, | 1987 |
A case of progressive hemichorea responsive to high-dose reserpine.
Topics: Aged; Amitriptyline; Chorea; Dyskinesia, Drug-Induced; Female; Humans; Perphenazine; Reserpine; Subs | 1986 |